Long-term Safety and Efficacy of Deutetrabenazine in Younger and Older Patients With Tardive Dyskinesia
Objective: To assess the long-term safety and efficacy of deutetrabenazine in younger (<55 years) and older (≥55 years) patients with tardive dyskinesia (TD). Background: TD…Prospective investigation of the frequency of tardive syndromes in outpatients attending two specialist psychiatry hospitals in Lagos, Nigeria
Objective: To determine the frequency and profile of TS in persons on antipsychotics attending tertiary psychiatry hospitals. Background: The term tardive syndrome (TS) encompasses the…Belly dancer’s dyskinesia due to prochlorperazine
Objective: We aim to present a case report of abdominal wall dyskinesia as a tardive syndrome of prochlorperazine. Background: The clinical presentation of involuntary choreiform…Real-World Evaluation of Patient Characteristics and Disease Management in Long-Term Valbenazine Treatment in Adults with Tardive Dyskinesia
Objective: To assess the clinical characteristics and overall disease management of adult patients receiving long-term valbenazine treatment for tardive dyskinesia (TD) in a real-world setting.…Patient Perspective of Tardive Dyskinesia: Results from a Social Media Listening Study
Objective: To use social media listening (SML) to understand the impact of symptoms on patients with assumed/self-reported tardive dyskinesia (TD). Background: TD is a persistent…Real-World Use and Impact of VMAT2 Inhibitors in Patients with Tardive Dyskinesia
Objective: To describe symptom impact and treatment outcomes in patients prescribed vesicular monoamine 2 (VMAT2) inhibitors for the treatment of tardive dyskinesia (TD). Background: TD,…Long-Term Outcomes with Valbenazine 40 mg/day in Adults with Tardive Dyskinesia
Objective: To examine long-term outcomes in adults with tardive dyskinesia (TD) who received once-daily valbenazine (VBZ) 40 mg or had a dose reduction from 80…Clonazepam as a cure or a cause? : Withdrawal Emergent Syndrome
Objective: To report a case of clonazepam induced withdrawal emergent dyskinesia. Background: Withdrawal emergent syndrome was first described in 1973 when it was noticed that…An Experimental Study to Assess the Professional and Social Consequences of Tardive Dyskinesia
Objective: Evaluate the impact of orofacial tardive dyskinesia (TD) symptoms on the professional and social lives of patients with TD. Background: TD, a movement disorder…Clinically Relevant Changes in AIMS Based on Clinical and Patient Global Impression of Change in Patients With Tardive Dyskinesia Treated with Deutetrabenazine
Objective: To assess clinically relevant reductions with treatment of deutetrabenazine in abnormal involuntary movements in patients with tardive dyskinesia (TD), as evidenced by correlation between…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 8
- Next Page »